Watch the interview with Aqilions vd Sarah Fredriksson below.
Aqilion develops treatments for diseases caused by chronic inflammation. In addition to the three projects already in the company's pipeline, a new program targeting PKCtheta was recently announced. CEO Sarah Fredriksson came to BioStock's studio to tell us more about the company's new venture!